Request Free Sample ×
Breast Biopsy Market Research Report – Forecast to 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Breast Biopsy Market

ID: MRFR/MED/4827-CR
144 Pages
Rahul Gotadki
Last Updated: March 28, 2026

Breast Biopsy Market Research Report: Size, Share, Trend Analysis By Product Type (Biopsy Needles, Biopsy Tables, Biopsy Wires, Guidance Systems, and others), By Technique Type (Fine Needle Aspiration Biopsy, Core Needle Biopsy, Biopsy Markers, MRI-Guided Core Needle Biopsy, Surgical Biopsy, Wire Localization, Sentinel Node Biopsy), By Guidance Technique (Ultrasound-Guided Biopsy, Mammography Guided Magnetic Resonance, CT Guided Biopsy, Other Image-Guided Breast Biopsy (PET and Thermography), By End-User (Hospitals and Clinics, Diagnostics and Imaging Centers, Academic and Research Institutes, and Others) And by Region (North America, Europe, Asia-Pacific, And Rest of The World) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Breast Biopsy Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Methodology Download PDF

Breast Biopsy Market Summary

As per MRFR analysis, the Breast Biopsy Market Size was estimated at 704.65 USD Million in 2024. The Breast Biopsy industry is projected to grow from 775.84 in 2025 to 2031.06 by 2035, exhibiting a compound annual growth rate (CAGR) of 10.1% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Breast Biopsy Market is experiencing robust growth driven by technological advancements and increasing demand for minimally invasive procedures.

  • North America remains the largest market for breast biopsy procedures, driven by advanced healthcare infrastructure and high awareness levels.
  • The Asia-Pacific region is emerging as the fastest-growing market, fueled by increasing healthcare investments and rising breast cancer incidence.
  • Ultrasound-Guided Biopsy continues to dominate the market, while Vacuum-Assisted Biopsy is witnessing rapid growth due to its efficiency and patient comfort.
  • Key market drivers include the rising incidence of breast cancer and the growing demand for minimally invasive procedures, supported by regulatory frameworks.

Market Size & Forecast

2024 Market Size 704.65 (USD Million)
2035 Market Size 2031.06 (USD Million)
CAGR (2025 - 2035) 10.1%

Major Players

Hologic (US), BD (US), Siemens Healthineers (DE), GE Healthcare (US), Philips (NL), Canon Medical Systems (JP), Fujifilm (JP), Medtronic (IE), C.R. Bard (US)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Breast Biopsy Market Trends

The Breast Biopsy Market is currently experiencing a notable transformation, driven by advancements in technology and an increasing emphasis on early detection of breast cancer. Innovations in imaging techniques, such as digital mammography and MRI-guided biopsies, are enhancing the accuracy and efficiency of procedures. Furthermore, the growing awareness surrounding breast health is prompting more women to seek preventive measures, thereby expanding the market's reach. As healthcare systems evolve, the integration of minimally invasive techniques is becoming more prevalent, which may lead to improved patient outcomes and satisfaction. In addition, the Breast Biopsy Market is witnessing a shift towards personalized medicine, where treatment plans are tailored to individual patient needs. This trend is likely to be influenced by ongoing research into genetic markers and biomarkers that can guide biopsy decisions. The increasing collaboration between healthcare providers and technology companies suggests a future where diagnostic processes are not only more precise but also more accessible. Overall, the Breast Biopsy Market appears poised for growth, with a focus on innovation and patient-centered care shaping its trajectory.

Technological Advancements

The Breast Biopsy Market is significantly influenced by ongoing technological innovations. Enhanced imaging modalities, such as ultrasound and MRI, are improving the precision of biopsy procedures. These advancements facilitate earlier detection and more accurate diagnoses, which may lead to better treatment outcomes.

Minimally Invasive Techniques

There is a growing trend towards minimally invasive biopsy methods within the Breast Biopsy Market. Techniques such as vacuum-assisted biopsies are gaining traction due to their reduced recovery times and lower complication rates. This shift is likely to enhance patient comfort and satisfaction.

Personalized Medicine

The Breast Biopsy Market is increasingly embracing the concept of personalized medicine. Tailoring biopsy approaches based on individual patient profiles and genetic information may optimize treatment strategies. This trend reflects a broader movement towards individualized healthcare solutions.

Breast Biopsy Market Drivers

Increasing Incidence of Breast Cancer

The rising incidence of breast cancer globally is a primary driver of the Global Breast Biopsy Market Industry. According to health statistics, breast cancer remains one of the most prevalent cancers among women, with millions diagnosed annually. This alarming trend necessitates advanced diagnostic methods, including biopsies, to ensure timely and accurate detection. As the population ages and awareness increases, the demand for breast biopsies is likely to grow. In 2024, the market is projected to reach 0.76 USD Billion, reflecting the urgent need for effective diagnostic solutions in the Global Breast Biopsy Market Industry.

Rising Awareness and Screening Programs

Increased awareness of breast cancer and the importance of early detection is driving the Global Breast Biopsy Market Industry. Public health campaigns and screening programs have led to more women participating in regular check-ups, resulting in higher biopsy rates. This proactive approach to health is crucial in identifying potential malignancies at an early stage. As educational initiatives continue to proliferate, the market is likely to see sustained growth. The projected compound annual growth rate of 7.51% from 2025 to 2035 underscores the potential for expansion in the Global Breast Biopsy Market Industry.

Regulatory Support and Reimbursement Policies

Regulatory support and favorable reimbursement policies are pivotal in shaping the Global Breast Biopsy Market Industry. Governments and health organizations are increasingly recognizing the importance of breast cancer screening and diagnosis, leading to improved reimbursement frameworks for biopsy procedures. This financial support encourages healthcare providers to offer these essential services, thereby increasing patient access. As policies evolve to support early detection and treatment, the market is poised for growth. The anticipated rise in market value from 0.76 USD Billion in 2024 to 1.68 USD Billion by 2035 indicates a positive outlook for the Global Breast Biopsy Market Industry.

Technological Advancements in Biopsy Techniques

Technological innovations in biopsy procedures are significantly influencing the Global Breast Biopsy Market Industry. Techniques such as stereotactic biopsy, ultrasound-guided biopsy, and MRI-guided biopsy have improved accuracy and patient outcomes. These advancements not only enhance the precision of tissue sampling but also reduce patient discomfort and recovery time. As healthcare providers adopt these cutting-edge technologies, the market is expected to expand. The anticipated growth from 0.76 USD Billion in 2024 to 1.68 USD Billion by 2035 indicates a robust demand for innovative biopsy solutions within the Global Breast Biopsy Market Industry.

Growing Demand for Minimally Invasive Procedures

The shift towards minimally invasive procedures is reshaping the Global Breast Biopsy Market Industry. Patients increasingly prefer options that minimize surgical trauma and promote quicker recovery. Techniques such as vacuum-assisted biopsy and core needle biopsy align with this trend, offering effective alternatives to traditional surgical methods. This demand for less invasive options is likely to drive market growth as healthcare providers adapt to patient preferences. The market's growth trajectory, from 0.76 USD Billion in 2024 to an expected 1.68 USD Billion by 2035, reflects the increasing inclination towards minimally invasive diagnostic solutions in the Global Breast Biopsy Market Industry.

Market Segment Insights

By Application: Core Needle Biopsy (Largest) vs. Ultrasound-guided Biopsy (Fastest-Growing)

The Breast Biopsy Market is segmented into various applications, with Core Needle Biopsy emerging as the largest segment. It has gained significant popularity due to its effectiveness in obtaining adequate tissue samples for diagnosis. In contrast, Ultrasound-guided Biopsy is catching up quickly, showcasing rapid growth as it allows real-time imaging and guidance for precise needle placement, appealing to both clinicians and patients. Other techniques such as Stereotactic, MRI-guided, and Fine Needle Aspiration Biopsies hold smaller portions of the market but are still crucial for specific scenarios and breast lesion types. As awareness grows regarding breast health and the importance of early detection, the demand for breast biopsy procedures is on the rise. The increased prevalence of breast cancer, along with technological advances in imaging techniques, are key drivers of growth within this segment. Both Core Needle and Ultrasound-guided techniques are projected to witness continued interest, with professionals favoring methods that enhance patient safety, comfort, and diagnostic accuracy. Innovative advancements and the development of minimally invasive procedures are expected to sustain the positive trajectory of the Breast Biopsy Market throughout the forecast period.

Core Needle Biopsy (Dominant) vs. Ultrasound-guided Biopsy (Emerging)

Core Needle Biopsy is the dominant application in the Breast Biopsy Market, primarily due to its ability to provide larger samples compared to Fine Needle Aspiration Biopsy, facilitating more accurate diagnoses. It is widely adopted in various healthcare settings due to its effectiveness in diagnosing breast lesions. In contrast, Ultrasound-guided Biopsy represents an emerging application that is experiencing rapid growth. The advantages of real-time imaging allow for improved accuracy during procedures, attracting a growing number of practitioners. Both procedures are essential; however, the innovation and advancements in Ultrasound-guided techniques are likely to enhance their usage. As breast health becomes a priority, the synergy between Core Needle and Ultrasound-guided techniques will play a pivotal role in the evolution of breast biopsy applications.

By End Use: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the Breast Biopsy Market, hospitals hold the largest share due to their comprehensive diagnostic and treatment services, which often integrate breast biopsy procedures within broader patient care. This established infrastructure and access to advanced imaging technologies position hospitals as critical players in this segment. Diagnostic laboratories, while smaller in share, are rapidly increasing their footprint by offering specialized services and streamlined processes accessible to various healthcare providers, thus catering to a growing demand for biopsies. Growth trends within the End Use segment indicate a shift towards outpatient settings and diagnostic labs, where rapid advancements in technology are facilitating quicker and more efficient biopsy procedures. The rise in awareness about breast cancer screening and improvements in biopsy techniques are key drivers. Moreover, an increasing number of women seeking earlier diagnoses and minimally invasive procedures is fueling this growth, particularly in the diagnostic lab sector.

Hospitals (Dominant) vs. Research Institutions (Emerging)

Hospitals dominate the Breast Biopsy Market as they provide comprehensive care and possess the necessary facilities and personnel to perform complex biopsy procedures. Their established protocols, robust patient management systems, and advanced medical technologies allow them to achieve high levels of efficiency and precision in breast biopsy procedures. In contrast, research institutions are emerging as significant players; they contribute to innovation in biopsy technologies and methods. Their focus on clinical research and development allows them to explore novel techniques for improved diagnostics. While hospitals are characterized by their service delivery capacity, research institutions prioritize knowledge advancement, making them essential for future developments in biopsy methodologies.

By Type: Vacuum-assisted Biopsy (Largest) vs. Core Needle Biopsy (Fastest-Growing)

In the Breast Biopsy Market, the distribution of market share among the various biopsy types reveals that Vacuum-assisted Biopsy holds the largest segment. This technique has gained widespread adoption due to its efficiency and ability to obtain larger tissue samples. Core Needle Biopsy also plays a significant role, capturing substantial market interest with its less invasive approach compared to surgical biopsies. Fine Needle Aspiration Biopsy and Stereotactic Biopsy contribute to the market as well, but their shares are comparatively smaller, highlighting the dominance of the top two methods. Growth trends indicate that Core Needle Biopsy is the fastest-growing segment, driven by advancements in minimally invasive procedures and increasing patient awareness regarding early cancer detection. The demand for more accurate and less painful procedures is pushing healthcare providers to adopt these techniques, positioning Core Needle Biopsy as a key player in the market growth forecast. Additionally, the rise in breast cancer screening programs and favorable government initiatives are fueling the overall expansion of the Breast Biopsy Market, benefitting all segment types to some extent.

Vacuum-assisted Biopsy (Dominant) vs. Fine Needle Aspiration Biopsy (Emerging)

Vacuum-assisted Biopsy stands out as the dominant segment within the Breast Biopsy Market, primarily due to its ability to yield larger and more diagnostic tissue samples. This technique is particularly preferred in cases requiring comprehensive analysis, as it minimizes the number of necessary procedures and improves patient outcomes. On the other hand, Fine Needle Aspiration Biopsy, while emerging, provides a less invasive means of obtaining tissue samples with lower patient discomfort. Its growth is supported by an increased focus on outpatient procedures and technology enhancements in imaging and sampling techniques. Together, these two methods illustrate the evolving landscape of breast biopsy techniques, with one serving as the cornerstone of traditional practice and the other catering to the increasing demand for less invasive options.

By Technology: Needle-Based Technology (Largest) vs. Imaging Technology (Fastest-Growing)

In the Breast Biopsy Market, the Needle-Based Technology segment accounts for the largest share, signifying its established presence and preference among healthcare providers and patients. Following closely, the Imaging Technology segment has shown rapid growth due to advancements in imaging modalities, contributing significantly to the accuracy and effectiveness of biopsies. As demand for accurate diagnostic tools rises, these segments continue to reshape the market landscape, catering to diverse clinical needs.

Technology: Needle-Based (Dominant) vs. Imaging (Emerging)

Needle-Based Technology holds a dominant position in the Breast Biopsy Market due to its reliability and effectiveness in tissue sampling procedures. This segment encompasses various needle types that facilitate minimally invasive biopsies, ensuring precision and patient comfort. In contrast, Imaging Technology is emerging as a vital component of breast biopsies, enhancing detection and guiding procedures through advanced imaging techniques such as ultrasound and MRI. The growing emphasis on early diagnosis and personalized treatment plans is driving innovations in this segment, making it a crucial area of development within the market.

Get more detailed insights about Breast Biopsy Market
Request Free Sample

Regional Insights

North America : Market Leader in Innovation

North America continues to lead the Breast Biopsy Market, holding a significant share of 400.0M in 2024. The region's growth is driven by advanced healthcare infrastructure, increasing awareness of breast cancer screening, and supportive regulatory frameworks. The demand for minimally invasive procedures is rising, supported by technological advancements in imaging and biopsy techniques. Regulatory bodies are promoting early detection, further fueling market expansion. The competitive landscape in North America is robust, with key players like Hologic, BD, and GE Healthcare dominating the market. The U.S. is the primary contributor, benefiting from high healthcare expenditure and a strong focus on research and development. The presence of established companies ensures a steady supply of innovative products, enhancing patient outcomes and driving market growth. The region's commitment to improving healthcare access and quality is pivotal for future advancements.

Europe : Emerging Market with Growth Potential

Europe's Breast Biopsy Market is valued at 200.0M, showcasing significant growth potential. The region is experiencing an increase in breast cancer awareness and screening programs, driven by government initiatives and healthcare policies. Regulatory support for innovative biopsy technologies is also a key growth driver. The demand for accurate and less invasive procedures is rising, aligning with the region's focus on patient-centered care and improved diagnostic accuracy. Leading countries in Europe include Germany, France, and the UK, where healthcare systems are increasingly adopting advanced biopsy techniques. The competitive landscape features major players like Siemens Healthineers and Philips, who are investing in R&D to enhance their product offerings. The European market is characterized by a mix of established companies and emerging startups, fostering innovation and competition. This dynamic environment is expected to propel market growth in the coming years.

Asia-Pacific : Rapidly Growing Market Segment

The Asia-Pacific Breast Biopsy Market, valued at 80.0M, is witnessing rapid growth, driven by increasing healthcare investments and rising awareness of breast cancer. The region's expanding population and improving healthcare infrastructure are significant factors contributing to market expansion. Government initiatives aimed at enhancing cancer screening and treatment accessibility are also pivotal in driving demand for biopsy procedures, particularly in emerging economies. Countries like Japan, China, and India are leading the market, with a growing number of healthcare facilities adopting advanced biopsy technologies. Key players such as Canon Medical Systems and Fujifilm are actively participating in this growth, focusing on innovative solutions tailored to regional needs. The competitive landscape is evolving, with both multinational corporations and local firms striving to capture market share, thereby enhancing the overall market dynamics in the region.

Middle East and Africa : Untapped Market with Opportunities

The Middle East and Africa Breast Biopsy Market, valued at 24.65M, presents significant growth opportunities, driven by increasing healthcare investments and rising awareness of breast cancer. The region is gradually improving its healthcare infrastructure, which is essential for enhancing diagnostic capabilities. Government initiatives aimed at cancer awareness and screening programs are also contributing to market growth, as more patients seek early detection and treatment options. Leading countries in this region include South Africa and the UAE, where healthcare systems are increasingly adopting advanced biopsy technologies. The competitive landscape is characterized by a mix of local and international players, with companies like Medtronic and C.R. Bard making strides in the market. As the region continues to develop its healthcare sector, the demand for innovative biopsy solutions is expected to rise, creating a favorable environment for market expansion.

Breast Biopsy Market Regional Image

Key Players and Competitive Insights

The Breast Biopsy Market is currently characterized by a dynamic competitive landscape, driven by technological advancements, increasing awareness of breast cancer screening, and a growing emphasis on early diagnosis. Major players such as Hologic (US), BD (US), and Siemens Healthineers (DE) are strategically positioned to leverage innovation and expand their market presence. Hologic (US) focuses on enhancing its product portfolio through continuous research and development, while BD (US) emphasizes strategic partnerships to bolster its diagnostic capabilities. Siemens Healthineers (DE) is investing in digital transformation initiatives, which collectively shape a competitive environment that prioritizes technological superiority and operational efficiency.Key business tactics within the Breast Biopsy Market include localizing manufacturing and optimizing supply chains to enhance responsiveness to regional demands. The market structure appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for a diverse range of products and services, fostering competition that drives innovation and improves patient outcomes.

In November Hologic (US) announced the launch of its latest imaging system designed to improve the accuracy of breast biopsies. This strategic move is significant as it not only enhances Hologic's product offerings but also positions the company as a leader in precision diagnostics, potentially increasing its market share in a competitive landscape.

In October BD (US) expanded its partnership with a leading healthcare provider to enhance its breast biopsy solutions. This collaboration is likely to strengthen BD's market position by integrating advanced technologies into its offerings, thereby improving patient care and operational efficiencies.

In September Siemens Healthineers (DE) unveiled a new AI-driven software that assists radiologists in interpreting breast biopsy results more accurately. This innovation underscores the company's commitment to integrating artificial intelligence into its diagnostic processes, which may lead to improved diagnostic accuracy and faster patient turnaround times.

As of December the Breast Biopsy Market is witnessing trends such as digitalization, sustainability, and AI integration, which are reshaping competitive dynamics. Strategic alliances among key players are becoming increasingly prevalent, fostering innovation and enhancing product offerings. The competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological innovation, reliability in supply chains, and enhanced patient outcomes, indicating a shift towards a more sophisticated and value-driven market.

Key Companies in the Breast Biopsy Market include

Industry Developments

February 2023: The NovaSure V5 global endometrial ablation (GEA) device has been approved in Canada and Europe, according to Hologic Inc. This novel version has improved features that are intended to address a variety of cervical and uterine anatomies. It expands on NovaSure's stellar track record, which includes 3 million people who have benefited from the technology.

November 2022: Government representatives from Mexico and Baja California joined BD (Becton, Dickinson and Company), a major global provider of medical technology, to officially open a new $38.6 million manufacturing facility in Tijuana that will create tools and innovations that enhance medication safety in healthcare settings.

August 2022: The company's first twin stage core biopsy tool, the Mammotome DualCore biopsy system, was introduced by Mammotome. In addition to the Mammotome Elite Tetherless Vacuum-Assisted Biopsy Device (tetherless VABB) and the Mammotome Revolve Dual Vacuum-Assisted Breast Biopsy Market System, this new core biopsy device offers another choice in the Mammotome ultrasound-guided breast biopsy portfolio (tethered VABB).

Future Outlook

Breast Biopsy Market Future Outlook

The Breast Biopsy Market is projected to grow at a 10.1% CAGR from 2025 to 2035, driven by technological advancements, increasing breast cancer prevalence, and rising awareness.

New opportunities lie in:

  • Development of AI-driven imaging technologies for enhanced biopsy accuracy.
  • Expansion of minimally invasive biopsy techniques in outpatient settings.
  • Strategic partnerships with healthcare providers for integrated diagnostic solutions.

By 2035, the Breast Biopsy Market is expected to achieve substantial growth, reflecting evolving healthcare demands.

Market Segmentation

Breast Biopsy Market Type Outlook

  • Core Needle Biopsy
  • Fine Needle Aspiration Biopsy
  • Vacuum-Assisted Biopsy

Breast Biopsy Market End Use Outlook

  • Hospitals
  • Diagnostic Centers
  • Specialty Clinics

Breast Biopsy Market Technology Outlook

  • Needle-Based Technology
  • Imaging Technology
  • Biopsy Devices

Breast Biopsy Market Application Outlook

  • Stereotactic Biopsy
  • Ultrasound-Guided Biopsy
  • MRI-Guided Biopsy
  • Vacuum-Assisted Biopsy

Report Scope

MARKET SIZE 2024 704.65(USD Million)
MARKET SIZE 2025 775.84(USD Million)
MARKET SIZE 2035 2031.06(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 10.1% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Hologic (US), BD (US), Siemens Healthineers (DE), GE Healthcare (US), Philips (NL), Canon Medical Systems (JP), Fujifilm (JP), Medtronic (IE), C.R. Bard (US)
Segments Covered Application, End Use, Type, Technology
Key Market Opportunities Advancements in minimally invasive techniques enhance patient outcomes in the Breast Biopsy Market.
Key Market Dynamics Technological advancements in imaging and needle biopsy techniques drive growth in the Breast Biopsy Market.
Countries Covered North America, Europe, APAC, South America, MEA

Market Highlights

Author
Author
Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Get In Touch
Leave a Comment

FAQs

What is the current valuation of the Breast Biopsy Market?

The Breast Biopsy Market was valued at 704.65 USD Million in 2024.

What is the projected market size for the Breast Biopsy Market by 2035?

The market is expected to reach 2031.06 USD Million by 2035.

What is the expected CAGR for the Breast Biopsy Market during the forecast period 2025 - 2035?

The expected CAGR for the Breast Biopsy Market is 10.1% during the forecast period.

Which segment had the highest valuation in the Breast Biopsy Market in 2024?

The Core Needle Biopsy segment had the highest valuation at 430.48 USD Million in 2024.

What are the key players in the Breast Biopsy Market?

Key players include Hologic, BD, Siemens Healthineers, GE Healthcare, and Philips.

How does the Ultrasound-guided Biopsy segment perform in terms of market valuation?

The Ultrasound-guided Biopsy segment was valued at 105.7 USD Million in 2024 and is projected to grow significantly.

What is the market valuation for hospitals in the Breast Biopsy Market?

Hospitals accounted for a market valuation of 250.0 USD Million in 2024.

What is the projected growth for the Fine Needle Aspiration Biopsy segment by 2035?

The Fine Needle Aspiration Biopsy segment is expected to grow from 42.0 USD Million in 2024 to a higher valuation by 2035.

Which end-use segment is anticipated to show substantial growth in the Breast Biopsy Market?

The Diagnostic Laboratories segment, valued at 150.0 USD Million in 2024, is anticipated to show substantial growth.

What is the valuation of the Vacuum-assisted Biopsy segment in 2024?

The Vacuum-assisted Biopsy segment was valued at 150.0 USD Million in 2024.

Research Approach

Secondary Research

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) 510(k) Premarket Notification Database and PMA approvals, European Medicines Agency (EMA) medical device regulations, International Agency for Research on Cancer (IARC) GLOBOCAN database, National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program, Centers for Disease Control and Prevention (CDC) National Program of Cancer Registries (NPCR), World Health Organization (WHO) Global Health Observatory, European Commission European Cancer Information System (ECIS), American Society of Breast Surgeons (ASBrS), Society of Surgical Oncology (SSO), American College of Radiology (ACR) Breast Imaging Commission, Radiological Society of North America (RSNA), European Society of Breast Imaging (EUSOBI), European Society for Medical Oncology (ESMO), National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines, and national cancer registries from key markets including China (NCC), Japan (National Cancer Center), and India (National Cancer Registry Programme).

In order to compile breast cancer incidence and screening statistics, biopsy procedure volumes, regulatory approval pathways for Class II and III devices, clinical safety and efficacy studies, reimbursement policies, and competitive landscape analysis for needle-based biopsy systems, vacuum-assisted devices, stereotactic guidance systems, ultrasound-guided platforms, MRI-compatible biopsy devices, and emerging liquid biopsy technologies, these sources were employed.

Primary Research

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. Breast biopsy device manufacturers, imaging system OEMs, and consumable suppliers were among the supply-side sources, which included CEOs, VPs of Product Development, regulatory affairs chiefs, and commercial directors. Procurement leads from hospitals, ambulatory surgical centers, breast imaging centers, and comprehensive cancer institutes were included in the demand-side sources, which also included board-certified breast surgeons, radiologists who specialized in breast imaging, medical oncologists, and pathology laboratory directors. Primary research has confirmed the product pipeline timelines for automated biopsy systems and AI-integrated imaging platforms, and has gathered insights on clinical adoption patterns, pricing strategies, reimbursement dynamics for in-office vs. hospital-based procedures, and physician preference trends toward minimally invasive diagnostic techniques. The market segmentation is validated by product type (biopsy needles, guidance systems, tables, localization wires), procedure type (core needle, vacuum-assisted, fine needle aspiration, open surgical, liquid biopsy), and guidance technology (stereotactic, ultrasound, MRI).

Primary Respondent Breakdown:

By Designation: C-level Primaries (40%), Director Level (25%), Others (35%)

By Region: North America (38%), Europe (30%), Asia-Pacific (25%), Rest of World (7%)

Market Size Estimation

Revenue mapping and procedure volume analysis were implemented to determine global market valuation. The methodology comprised the following:

Identification of 35+ key manufacturers in North America, Europe, Asia-Pacific, Latin America, and the Middle East who specialize in breast biopsy needles, vacuum-assisted biopsy systems, stereotactic guidance platforms, ultrasound biopsy systems, MRI-compatible devices, and liquid biopsy assays

Product mapping encompasses core needle biopsy devices, vacuum-assisted biopsy (VAB) systems, fine needle aspiration (FNA) equipment, stereotactic guidance systems, ultrasound-guided biopsy platforms, MRI-guided biopsy platforms, biopsy tables, localization wires, and circulating tumor cell (CTC)/ctDNA liquid biopsy platforms.

Examination of annual revenues that are specific to breast biopsy device portfolios and imaging guidance systems, as reported and modeled

Manufacturers that account for 70-75% of the global market share in 2024 are included in the coverage.

Segment-specific valuations for biopsy needles, guidance systems, and liquid biopsy segments are derived through extrapolation using bottom-up (breast cancer screening volumes × biopsy compliance rates × procedure volume by guidance modality × average selling price by country) and top-down (manufacturer revenue validation, imaging center capital expenditure analysis) approaches.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓